POSEIDON Teaming Profiles
Thank you for showing an interest in ARPA-H’s Platform Optimizing SynBio for Early Intervention and Detection in ONcology (POSEIDON) program. This page is designed to help facilitate connections between prospective proposers. If either you or your organization are interested in teaming, please submit your information via the portal linked below. Your details will then be added to the list below, which is publicly available.
POSEIDON anticipates that teaming will be necessary to achieve the goals of the program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal to the POSEIDON solicitation.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.
Interested in learning more about the POSEIDON program?
POSEIDON Teaming Cards
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| Contact | Organization Name | Location | Description of Research Focus Area | Description of Teaming Partner | Technical Areas | |
| Chris Fitzsimmons | Carbon Technology, Inc. | chris.fitzsimmons@carbontekinc.com | Irvine, CA | Carbon Technology, Inc. leads in single walled carbon nanotube (CNT) electronic sensors. CNT's that bridge two electrodes are one of the most sensitive materials possible. Carbon Technology's pristinely grown CNT's, kept clean through device formation and including a bottom gate, result in sensors capable of amplifying the analyte-sensor interaction six orders of magnitude higher than "linear" resistance-based sensors. The end result is PicoMolar sensitivity. | With carbon nanotube synthesis control and proven high uniformity manufacturing, Carbon Technology, Inc. seeks partners with expertise in the following three areas: -Synthetic reporters -Access to biological sample -Investigational New Drug (IND) and clinical testing | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Chris Sommers | COTA, Inc. | chrissommers@cotahealthcare.com | . | COTA, founded in 2011 by oncologists, biostaticians, and data scientist, was established to address some of the most pressing research and clinical challenges in oncology. At its core, COTA combines deep oncology expertise with advanced technology to transform real-world data into high-quality, regulatory grade assets. These datasets support physician, scientists, and researchers in generating impactful evidence for both clinical practices and regulatory decision-making. | The COTA team brings extensive expertise in curating oncology data and conducting observational research in collaboration with partners across the life sciences and healthcare sectors. We aim to collaborate with organizations seeking high-quality real-world data to gain deeper insights into the patient journey, experience, and real-world outcomes | . |
| Hem Shukla | University of Maryland | hdshukla@som.umaryland.edu | . | University of Maryland School of Medicine located at the heart of Maryland, Washington DC and Virginia biotechnology research corridor. University of Maryland Greene Comprehensive Cancer Center is one of the eminent research center involved in patient treatment oriented research and new therapies. UMGCCC has developed some very important therapies which are being used worldwide. An example is Aromatase inhibitor to treat metastatic breast cancer. We have Proton Radiation Center to treat cancer | We have initiated a pilot scale study on Precision Medicine to grow cancer patient derived tumor organoids under 3-D condition in the lab while patient is being treated in the clinic. These tumor organoids could be grown in two weeks and could be used to treat with the drugs and radiation and find out right combination which could effectively kill tumor. We are also developing circulating tumor DNA (ctDNA) kit for early cancer detection and we have published our research in cancer journals. | . |
| Samuel Chen | Truly Technologies | contact@truly-technologies.com | . | Truly Technologies develops innovative biofluid specimen (e.g., urine, saliva) collection and processing devices. Our core technology utilizes osmosis to efficiently concentrate biomarkers (e.g., nucleic acids, proteins, glycolipids, exosomes) and remove background matrices, improving the sensitivity and specificity of diagnostic assays. The scalable and customizable device offers a cost-effective solution for analyte separation with exceptional yield and purity. | Truly Technologies seeks partners developing cancer diagnostic assays for rapid screening. We're looking for collaborators who can benefit from our sample processing technology to enhance the sensitivity and specificity of their assays. Ideal partners are those with access to clinical samples with assay evaluation capabilities, enabling joint effort to improve the diagnostic accuracy and streamline cancer detection workflows. | . |
| Shirali Nigam | Cogitamentum Bio | shirali@cogitamentumbio.com | . | At Cogitamentum Bio, we combine rigorous research expertise with strategic business acumen to drive the successful commercialization of biomedical technologies. Our services span in-depth market research, healthcare product management, business development, and AI-driven data solutions to accelerate product-market fit and adoption. We specialize in identifying high-impact applications, fostering strategic partnerships, and empowering biotech startups to scale and secure funding. | In addition to commercialization support, we’re eager to step in as the Engagement Officer. Our team members bring extensive experience from prior roles in 'Access to and Quality of Care', collaborating with state governments, insurances, patient groups, providers, CMS, and government officials. Their work on rollouts of COVID-testing and vaccines equips Cogitamentum Bio to effectively address healthcare access challenges, all while applying a human-centered design approach. | . |
| Yuhwa Lo | UCSD | ylo@ucsd.edu | . | TA 1/TA2: Synthetic protein/peptide biosensors with AL/ML for disease fingerprint, sensor signal transduction with CMOS and CNTs, microfluidics and system integration, patient samples from cancer center, telemedicine and EHR. | TA 2 kit GMP manufacturing, sample (urine and breadth) collection, patient recruiting. | . |
| Amanda Ellis | Grand Strand Clinical Trial Services | amandaellis@gsclinical.com | . | GSCTS provides scientific consulting, medical writing, operational support, and outsourcing support. | GSCTS is looking to support teaming partners with the services we provide. | . |
| Julia Komissarchik | Glendor, Inc | julia@glendor.com | . | Glendor is on a quest to safeguard patients’ privacy by de-identifying Protected Health Information (PHI) while empowering BAA-free data sharing. Glendor PHI Sanitizer - automatic in situ PHI De-identification software that is easily integrated into the existing data workflow. | We are looking for partners who are interested in protecting patients privacy by deidentifying medical data prior and after data transfer and sharing. | . |
| Nune Martiros | General Inception | nune.martiros@generalinception.com | San Francisco and Boston, CA | We are a venture studio focused on engineered biology, life sciences tools, and diagnostics. | We are interested in serving as prime and commercial partner to bring together the right technologies to carry out POSEIDON's mission with a dedicated internal team. We have relevant technologies in many of our portfolio companies as well as a vast industry and academic network. We are seeking out companies, academic groups, biobanks, and clinical partners looking for a prime to contribute to piecing together an ideal solution. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Jingcheng Ma | University of Notre Dame | jma9@nd.edu | Notre Dame, IN | Sensitive and affordable gas sensors for breath-based cancer detection: using complex fluid techniques to capture airborne biomarkers into concentrated droplets. Our platform can significantly enhance gas sensing sensitivity by several orders of magnitudes. Our platform can also seamlessly integrate with existing liquid or gas sensing platforms to detect dilute biomarkers beyond current capabilities. | We are open to working with partners who have a mature team, platform, and resources, and who are looking to further enhance the sensitivity of their existing biosensing platforms. Our platform also enables urine detection teams to detect exhaled breath metabolites using the same biosensing system. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| John Sadowski | Planned Systems International | Jsadowski@atlintl.com | Cincinnati, OH | PSI has experience with the health IT and electronic health records aspects of the program, and we can also serve as a commercialization partner due to our extensive experience winning and performing services contracts with the U.S. federal government. | We are seeking technical partners who have scientific capabilities required by the program, but need a partner for the IT, commercialization, or regulatory aspects of the program. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Hongwei Sun | Northeastern University | ho.sun@northeastern.edu | Boston, MA | My group at Northeastern University and collaborators have developed a portable, low-cost acoustic wave-based sensing system with machine learning capabilities which is being used for virus and biomarker detection in wastewater samples. The developed sensing system can be potentially used for cancer detection in both gas (e.g. breath) and liquid (e.g. urine) samples. | TA1 | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Diana Caldwell | Amplified Sciences | diana.caldwell@amplifiedsci.com | West Lafayette, IN | Amplified Sciences is a CLIA stage life science in-vitro diagnostics company with an ultra-sensitive molecular-sensing platform technology with composition of matter IP exclusively licensed from Purdue University focused on accurately detecting debilitating diseases sooner. Their lead assay a tool for risk stratification of pancreatic cancer demonstrates +95% NPV in ruling out potential malignancy in highrisk pancreatic cystic lesion patients and operates with 50x fluid volume than competition | Existing point of care devices leveraging optical platform and/or ELISA (FDA cleared preferred), teams with breath collection expertise, synergistic chemistry and optical platform tech, access to large banks of samples | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| James Wilking | Mayo Clinic | Wilking.james@mayo.edu | Rochester, MN | We are a group of biomedical engineers with expertise in microfluidics and diagnostics, working with a group of oncologists. | We are potentially looking for partners with synthetic biology expertise. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Veerle Reumers | imec USA | veerle.reumers@imec-int.com | Boston, MA | At imec, we have a long history of applying scalable CMOS technologies for the betterment of human health. Of specific interest for the non-invasive detection and classification of cancers are our multiplex sensing technologies such as our portable and affordable surface sensitive point-of-care biosensors, nanopore based molecular sensors for continuous patient monitoring and our nano-mesh based breath aerosol samplers for non-invasive sample extraction. | We are seeking collaborations with organizations with expertise in high throughput molecular screening for the identification of relevant target molecules and also organizations with expertise in high performance multiplex assay development. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Rebekah Goetz | Memorial Sloan-Kettering Cancer Center | goetzr@mskcc.org | New York, NY | The MSKCC Biomarker Development Program has deep expertise in ctDNA analysis and biomarker development in oncology. We have deep clinical experience with a particular interest in early cancer detection. MSK is one of the highest volume cancer centers in the world. | Sensor Design & Development: Expertise in synthetic biology, focusing on cell-free and cell-based sensors for cancer detection. Medical Device Engineering: Experience in developing low-cost, user-friendly at-home cancer screening devices, including multiplexed detection systems Commercial Expertise: Proven success in navigating diagnostics regulatory landscapes and commercializing health technologies for broad accessibility Data Integration & Analysis: Proficiency in AI/ML integrating with EHR | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Gary Puckrein | National Minority Quality Forum | gpuckrein@nmqf.org | National, DC | The Cancer Stage Shifting Initiative (CSSI) is a multi-year, multi-site effort aligned with President Biden’s Cancer Moonshot goal to reduce annual cancer-related deaths by 50%. CSSI aims to bring the benefits of the Cancer Moonshot to historically marginalized communities, focusing on equitable healthcare access and outcomes. | We are looking for partners who want to bring cutting edge science and technology to historically marginalized communities | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH |
| Siyang Zheng | Carnegie Mellon University | siyangz@andrew.cmu.edu | Pittsburgh, PA | We have developed technologies for liquid biopsy, focusing on isolating extracellular vesicles from body fluids such as plasma and urine, and detecting cancer-related biomarkers, including mutations and methylation. Additionally, we have developed intracellular protein and nucleic acid delivery methods using MOF nanoparticles and extracellular vesicles. We also have experience in detecting volatile organic compounds (VOCs) using microfabricated devices and insect antennae. | synthetic biology | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Francesco Gatto | Elypta | gatto@elypta.com | Stockholm, Sweden | Elypta is a Swedish diagnostic company pioneering glycosaminoglycans (GAG) as a novel class of metabolic biomarkers to assess the risk and early development of multiple cancers while asymptomatic. Our goal is to commercialise affordable mass spectrometry (UPLC-MS/MS) IVD kits for small volumes of self-sampled urine supporting scalable distribution. GAGs appear to be powerful biomarkers for many cancer types (doi.org/10.1073/pnas.211532811) and complement clinical and genomic information. | Biosensor development. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Ting Pang | Draper | tpang@draper.com | Cambridge, MA | Draper is a not-for-profit R&D corporation with >1,800 engineers and biologists working together in extensive scientific laboratories including state-of-the-art equipment, and >12,000 ft2 of BSL-2 lab space. Draper's design, build, and test capabilities enable the development of solutions from early-stage concepts to integrated and refined systems successfully transitioned to the field. Draper seeks to apply our expertise in microfluidics, device integration, and synthetic biology to POSEIDON. | Draper is seeking partners with expertise in TA1 clinical sample collection and cancer biomarker identification, as well as TA2 telemedicine and Electronic Health Record systems, and partners for non-clinical and clinical studies. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Jonathan Good | Scentian Bio | jonathan@scentianbio.com | Auckland, New Zealand | Scentian Bio is developing biosensors which unlock the power of insect olfactory receptors to provide ultra-sensitive detection of VOC signatures. We are synthetically producing these ligand-gated ion channel proteins and embedding them in small, handheld flow cell. We track the ion currents an array of these receptors’ produce in response to VOC-binding and use AI to process these signals to enable disease diagnosis. | We are looking for partners with existing data sets for a range of different cancers. We are also seeking clinical partners to help design and develop the at home diagnostic experience. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH |
| George Holmes | Luventix | gbholmes@luventix.com | Henderson, NV | Luventix is developing a platform for building various medical tests. We utilize urine to create the digital twin representing an organisms metabolic state. Our technology does not require us to identify the specific metabolites, we use raw data from the GC. Our raw signal approach effectively analyzes an input dataset with much larger dimensionality than current metabolite marker-based approaches. | We would be interested in participating in any test development or clinical trial that collects urine samples from patients and would share with us 10mL+ of urine per patient. We would be happy to be part of a joint test development program, with a leading PI from the partner. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Yujing Song | New York University | ys6780@nyu.edu | Brooklyn, New York City, NY | I am a research assistant professor at NYU. My work focuses on developing novel microfluidic biochips, point-of-care biosensors and sequencing technologies with single-molecule sensitivity, to advance cancer biomarker detection and biomarker-guided treatments. | We are seeking collaborations with biomarker researchers who specialize in identifying and validating clinically proven cancer biomarkers, particularly low-abundant markers, or clinical doctors with access to patient samples or established cancer models interested in partnering to improve treatment through biomarker-guided approaches. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Bidisha Pal | Thoreau Lab for Global Health | bpal@thoreaulab.org | Lowell, MA | Thoreau Lab for Global Health is focused on developing innovative diagnostic platforms for early cancer biomarker detection. We focus on identifying biomarkers in biofluids like saliva, breath, and blood. Collaborating with KaviKrishna Lab of India,we're translating findings into point-of-care devices for early detection, particularly for head and neck & lung cancers,impacting global health. Our work has identified IL-8 and LPS in saliva as potential biomarkers for head and neck cancer. | 1) Microfluidics & Sensor Technology: We seek experts to miniaturize and optimize our diagnostic platforms for point-of-care use, enhancing sensitivity & specificity. Currently, we are partnering with Advanced Silicone Group to validate biosensors that detect EGFR mutation in the blood of lung cancer patients. 2) Commercialization: We aim to collaborate with biotechnology incubators such as M2D2 at UMass Lowell to develop effective business models ensuring widespread access to our innovations. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Erik Young | Quicksilver Biosciences, Inc. | efy@quicksilverbiosciences.com | New York, NY | Quicksilver Biosciences is advancing biosensing tools using Carbon Nanotube Field Effect Transistors integrated with Complementary Metal Oxide Semiconductor electronics. Our sensors function with no enzymes, labels, tags or fluorophores. The technology is adaptable to various target molecules and scalable for diverse applications. We have created high density multiplex sensors with the ability to detect multiple targets. Our current chip features 64,000 addressable devices. | We seek team partners with proficiency in the POSEIDON TA1 spaces to align with our strengths in the TA2 space. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Patrick Lawless | Stanford University | plawless@stanford.edu | Palo Alto, CA | The Soh Lab's research focuses on development of novel point of use diagnostics tests that can be used in low resource settings by previously untrained personnel. The lab develops novel reagents, assays and devices to perform quantitative determinations of clinically relevant biomarkers (peptides, proteins, nucleic acids, etc) in biological samples. | The lab is seeking potential teaming partners with demonstrated expertise in sensor and synthetic reporter development for biomarkers relevant to early cancer detection. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Xudong Fan | University of Michigan | xsfan@umich.edu | Ann Arbor, MI | My lab at Univ. Michigan is developing portable, hand-held, and wearable micro-gas chromatography (GC) devices for breath and skin-emission (body odor) analysis. The devices are being used in hospitals for clinical studies including cancer studies. The devices can be used in one-time detection or continuous disease tracking. Meanwhile, we are reducing the micro-GC costs for home use. UM Rogel Cancer Center has strong cancer research and clinics, and data analysis capabilities. | TA1 | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Caoimhe Walsh | Imperial College London | caoimhe.walsh@imperial.ac.uk | 7th Floor Commonwealth Building - Imperial College London, Du Cane Road, W12 0NN, London, UK | The VOC laboratory at Imperial College London has >15 years expertise in VOC biomarker research for cancer detection. We are conducting clinical trials in >40,000 subjects with oesophageal, gastric, colorectal, pancreatic and liver cancers and benign conditions to develop and validate a breath test to detect multiple gastrointestinal cancers (25% of all cancers). We have developed robust quality management systems for processing and analysing breath and urine VOCs using GC-MS. | Our vision is a home-based breath test utilising a sensor-based technology. We hold IP for our reliable breath collection system and volatile biomarkers for gastrointestinal cancers discovered in our clinical studies, however our method for analysing breath VOCs uses laboratory-based GC-MS. Partners with expertise in sensors technology would translate our technology to a home device. We also seek partners working in non-gastrointestinal cancers to complete the development of a multi-cancer test. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Andre Teixeira | Institute for Protein Innovation | andre.teixeira@proteininnovation.org | Boston, MA | The Institute for Protein Innovation (IPI) established a high throughput (HT) platform that develops antibodies to cell surface targets. IPI’s approach evaluates entire cell surface protein families, generating highly specific antibodies with low cross-reactivity through expertise in - Antigen design, expression, and purification - Recombinant antibody and nanobody discovery (>200/yr) - HT production, testing and characterization of IgGs (>5,000/yr) | IPI is seeking teams to collaborate with who have expertise in cancer cell biology and cancer biomarkers to aid in identifying and validating and potential targets for antibody development. IPI also seeks collaboration with teams who have engineering expertise with incorporating antibodies into stable testing devices. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Mike Walden | Institute for Protein Innovation | mike.walden@proteininnovation.org | Boston, MA | The Institute for Protein Innovation (IPI) established a high throughput (HT) platform that develops antibodies to cell surface targets. IPI’s approach evaluates entire cell surface protein families, generating highly specific antibodies with low cross-reactivity through expertise in: - Antigen design, expression, and purification - Recombinant antibody and nanobody discovery (>200/yr) - HT production, testing and characterization of IgGs (>5,000/yr) | IPI is seeking teams to collaborate with who have expertise in cancer cell biology and cancer biomarkers to aid in identifying and validating and potential targets for antibody development. IPI also seeks collaboration with teams who have engineering expertise with incorporating antibodies into stable testing devices. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| James White | Resphera Biosciences | jwhite@respherabio.com | Baltimore, MD | Resphera Biosciences delivers cutting-edge computational and biostatistical analysis, focused on advancing translational research in medicine and biotechnology, with a particular emphasis on cancer, microbiome, and immunology. | Resphera Biosciences is looking to team up with partners who will require comprehensive biostatistical and computational analyses from the initial development phase through verification and validation studies. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| John Sadowski | Planned Systems International | Jsadowski@atlintl.com | Cincinnati, OH | Health IT, nanosensors | Experience with regulatory aspects | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Imran Haq | The Sample Network Limited | imranhaq@thesamplenetwork.co.uk | London, UK | We are experiences in performing clinical collections, and sample provision across oncological indications | Lead partners that we can support with clinical samples for technology development and validation. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Anubhav Dubey | Grafton Biosciences | ad@graftonbio.com | Atlanta, GA | Grafton Biosciences was founded to develop a multi-cancer early detection test with a fully at-home (untrained users) intended use. The underlying principle involves simultaneous multi-sample (breath, urine, and saliva), multi-omics (RNA, proteins, and metabolites) sensing with massively parallel detection of hundreds of targets. These biological targets would be paired with synthetic analytes (TA1), all in the same Level 0 (OTC) test. The base platform has established manufacturing capacity. | Grafton Biosciences is looking for: 1) partners with solutions on the synthetic biology side, and 2) partners with retrospective repositories of cancer samples across target indications. That said, Grafton would be glad to have discussions with other types of partners that can support our solution. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Alexei Teague | Univeristy of MA, Lowell | alexei_teague@uml.edu | Lowell, MA | UMass M2D2 is a medtech/biotech startup incubator and accelerator that is a collaboration between UMass Lowell and UMass Chan Medical School. We provide a host of different services that are needed to advance startup companies, from regulatory guidance, help with IP, connections to venture capitalists, to product development. These are just a few of the services our program offers in addition to access to world class researchers and students eager to be involved in the innovation ecosystem. | UMass Lowell and UMass Chan Medical school are looking for partners who need help from an entrepreneurial support organization and collaborations with researchers from both UMass Lowell and UMass Chan Medical School. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Chris Hodkinson | Owlstone Medical | chris.hodkinson@owlstone.co.uk | Cambridge, United Kingdom | We are focussed on breath biomarker and have designed a synthetic sensors and volatile reporter for lung cancer and other diseases. The lung cancer sensor has been manufactured to GMP standards, been tested pre-clinically and in phase 1 human safety trials with the sensor delivery and breath collect designed for consumer use. We have developed at-home devices for real time analysis of breath linked to a SmartPhone App for test reporting; the device is FDA and UK approved and on the market. | We are seeking potential partners with expertise in synthetic biology with novel cancer targeting mechanisms. We are open to partnerships with industry, academic and not-for-profit organisations. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Ashkan Afshin | Novelna Inc. | ashkan@novelna.com | Palo Alto, CA | Novelna is focused on developing first-in-class proteomics-based liquid biopsy tests for early cancer detection. The company has already developed a blood-based test for early detection and is now targeting the creation of non-invasive diagnostics to identify multiple cancer types at early stages, aiming to improve outcomes and reduce healthcare costs by enabling timely interventions. | We are seeking partners with expertise in real-time protein measurement in bodily fluids. Additionally, we are interested in collaborating with organizations skilled in at-home sample collection that preserves protein integrity. These partnerships will facilitate the advancement of our non-invasive diagnostics for early cancer detection. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Jo Bhakdi | Quantgene | jb@quantgene.com | Portland, OR | Quantgene has developed Medical Intelligence platform to combine multi-omic and multi-modal signals to determine the possible presence of all cancers at early stages. The platform is currently in clinical and commercial deployment in multi-modal universal cancer screening solutions and combines cfDNA, medical history, genetics, personal risk factors and imaging signals.. | For an at-home solution, we need partners who can manufacture at-home devices as well as multi-omics assays whose signals would be combined with additional patient data by Quantgene's Medical Intelligence systems . | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH |
| Maria Cabezas | Northwestern University | m-cabezas@northwestern.edu | Evanston, IL | Prof. Shana Kelley's group is focused on developing novel analytical tools for biomarker monitoring. Our ultra sensitive electroanalytical methods integrate chip-based sensors made from nano materials with affinity reagents that enable molecular readouts of nucleic acid sequences, small molecules, and protein biomarkers. These systems are applicable to point-of-care diagnostics, as well as wearable and implantable sensors for continuous in vivo monitoring. | Our group is eager to collaborate in challenging projects with partners having expertise in the areas of synthetic biology, cancer genomics, and big data solutions. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| George Hanna | Imperial College London | pa.georgehanna@imperial.ac.uk | 7th Floor Commonwealth Building - Imperial College London, Du Cane Road, W12 0NN, UK | I established the VOC laboratory at Imperial College London, with >15 years expertise in VOC biomarker research for cancer detection. We are conducting clinical trials in >40,000 subjects with oesophageal, gastric, colorectal, pancreatic and liver cancers and benign conditions to develop and validate a breath test to detect multiple gastrointestinal cancers (25% of all cancers). We have developed robust quality management systems for processing and analysing breath and urine VOCs using GC-MS. | Our vision is a home-based breath test utilising a sensor-based technology. We hold IP for our reliable breath collection system and volatile biomarkers for gastrointestinal cancers discovered in our clinical studies, however our method for analysing breath VOCs uses laboratory-based GC-MS. Partners with expertise in sensors technology would translate our technology to a home device. We also seek partners working in non-gastrointestinal cancers to complete the development of a multi-cancer test. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Surath Gomis | Arma Biosciences | surath.gomis@arma-bio.com | Chicago, IL | Arma Biosciences has developed a universal biosensor platform for remote diagnostics which enables untrained users to perform tests in large quantities and at low cost for a range of diagnostic targets in cardiology, oncology, kidney disease, women's health, inflammation, and diabetes. Arma's primary commercial focus is in developing a handheld finger-prick blood remote monitoring system for heart failure patients in the home setting. | We are looking for supplemental expertise in synthetic biology, molecular biology, electrochemistry, and software development. Any teams that can complement our expertise in sensor development and diagnostics hardware is sought after. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Paul Dempsey | Hawkeye Bio, Inc | pdempsey@hawkeyebio.com | Torrance, CA | Using ultra sensitive graphene based biosensors to detect diagnostic enzyme activities from biological samples of patients. | We have ideas about how to adapt point of care fluorescence or luminescence based readers to a MCED application. These devices are already well know. We require an experienced partner to interface the device with the platform. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Jim Schwoebel | Quome Inc. | jim@quome.com | Los Angeles, CA | We have expertise in digital biomarker development (and AI/ML expertise with a data science team composed of a Chief Science Officer, +4 data scientists) and are building a healthcare cloud. | We are looking for research institutions and research collaborations that are in need of CTOs and software engineers to help move their research in urine/breath sensor biomarkers to submit a proposal. We have a technical team to help build infrastructure to support biomarker development as well as a team of data scientists fully capable of building ML models for this problem area. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Andre de Fusco | Hawkeye Bio, Inc. | adefusco@hawkeyebio.com | Los Angeles, CA | Hawkeye develops ultra-low cost cancer tests for population-scale deployment; our first program is in lung cancer with a focus on asymptomatic disease. Our graphene biosensors detect early cancer signatures by correlation to protease activity. Our lung test has been clinically validated and is entering production in 2024. Hawkeye’s biosensor platform is customizable and has been investigated in 14 cancers to produce MCED and MRD panels. | Hawkeye would like to identify partners with complementary technology and the ability to fund clinical validation trials across multiple indications. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Noorul Ali | ASBL Inc. | manonthemoon13131@gmail.com | Medford, MA | Automated synthetic biology labs. ASBL builds ASBL Lab 0 (bacterial and mammalian feeder), Lab 1 (bacterial genetic engineering), Lab 2 (mammalian genetic engineering). Our primary cellular engineering agent is mRNA. | Experience in genetic engineering, cell line development, and cancer expertise. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH |
| David Wong | University of California Los Angeles | dwong@dentistry.ucla.edu | Los Angeles, CA | Liquid biopsy for early cancer detection | Patient cohorts for the 30+ cancers (early stage I) | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Reuben Cummings | Nerevu Group | rcummings@nerevu.com | Peoria, IL | At Nerevu (pronounced {nay-RAY-voo}), we specialize in software integration, AI/ML analytics, and data management. Our expertise aligns closely with TA2, focusing on the software components of the MCED test kit. Additionally, we bring value in the areas of software integration, analytical validation, test evolution, and data sharing. | We are looking to team with medical and/or hardware focused organization to cover TA1 and the hardware components of the MCED test kit (TA2). | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Edward Strong | Natera, Inc. | estrong@natera.com | San Carlos, CA | Natera, Inc. is an assay developer and global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Our workflow combines high-yield DNA extraction with proprietary library preparation and bioinformatics. In the blood, we’ve set the industry standard by creating cfDNA tests with greater than 99% accuracy and sensitivity down to a single DNA molecule. Ongoing research and development works to extend our capability beyond their current settings. | Natera is historically highly collaborative with external partners in industry and academia, and over 200 peer-reviewed publications. We would be interested to meet and get know those with expertise in biosensor engineering (reporter molecules and/or hardware development). | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| George Jackson | Base Pair Biotechnologies, Inc. | bill.jackson@basepairbio.com | Houston, TX | We have assembled a team (led by Base Pair Bio) that includes experts in synthetic aptamer affinity reagents, biosensors, masks for collection of exhaled breath, and renowned experts in cancer proteomics and metabolomics. Finally, our team includes a mature medical device firm with significant regulatory expertise. | To round out our team, we are seeking a CRO with relevant ADME/Tox, animal, and human clinical trial expertise. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH |
| George Holmes | Luventix | gbholmes@luventix.com | Henderson, NV | Developing a cost-effective diagnostics platform that significantly reduces healthcare costs by providing simple, non-invasive urine tests for multiple-disease detection and diagnosis. The Luventix technology platform enables the development of tests that can, from a single urine sample, diagnose a wide range of conditions, including oncological, inflammatory, chronic, and infectious diseases. | Partnering with large nationwide pharmacies that have access to patients that have opt'd in to participate in CLinical studies | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Eduardo Reategui | The Ohio State University | reategui.8@osu.edu | Columbus, OH | developing microfluidic, biomaterial, and molecular-imaging methods for high-throughput sorting and molecular profiling of circulating disease biomarkers for cancer and infectious disease diagnosis. | complementary expertise in breath-based detection | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Mark Woollam | Integrated Nanosystem Development Institute | mwoollam@iu.edu | Indianapolis, IN | Our focus area is to identify volatile organic compound (VOC) biomarkers for human diseases, including various types of cancer, that are noninvasively expressed in breath or urine. This data is leveraged to design/optimize point-of-care detection systems that can be used in-clinic or at-home to enable early cancer detection. Devices that the team has experience in include portable mass analyzers, in-house chemiresistive sensors, as well as commercial metal oxide-based nanosensor arrays. | Potential partners include other TA 1 performers with expertise in synthetic biology to develop sensors for the detection of other biomarkers, including metabolites, proteins, and nucleic acids. We want to collaborate with industry performers focusing on TA 2 (breath and urine) that have wide ranging expertise in regulatory approvals/commercialization to help scale hardware and produce software that will be incorporated into a Multi-Cancer Early Detection (MCED) kit for at-home screening. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Xiaohui Ni | EarlyDiagnostics Inc. | xiaohui.ni@earlydx.com | 30601 Agoura Rd, Agoura Hills, CA 91301, CA | EarlyDiagnostics Inc. is a startup focused on providing accurate, affordable, non-invasive liquid biopsy products for early cancer diagnosis and a diagnostics platform for precision medicine. Our blood-based cfDNA test combines advanced assays with machine learning to detect cancer early and determine its location. Our cloud-based analytics platform integrates big data and AI/ML to support precision medicine decisions using multi-omics and imaging data. | Our team has extensive experience in cell-free DNA and protein biomarkers for multi-cancer detection, having analyzed over 4,000 blood samples across more than 10 cancer types. We seek partnerships with engineering teams to integrate our cell-free DNA/protein analysis into a microfluidic device for urine-based multi-cancer testing. | . |
| Min Xue | Icahn School of Medicine at Mount Sinai | min.xue@mssm.edu | New York, NY | We have three main research thrusts: 1. Chemical methods for multiplex single-cell assays targeting protein and metabolites. 2. Enzyme-responsive probes for bioanalytical analysis and disease diagnosis. 3. Peptide-based probes for specific recognition of protein epitopes and metabolites. | We are looking for partners with biomarker discovery and device development expertise. Ideally, we will develop simple and robust assays for the identified biomarkers, and work with the device development team to implement the assay. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Grum Teklemariam | gSpin Technologies LLC | GrumT@gSpinTech.com | Fairfax, VA | Magnetic resonance spectroscopy with quantum enhanced sensing | Clinical expertise | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Jasmine Zhou | EarlyDx | jasmine.zhou@earlydx.com | Los Angeles, CA | We developed a technology to sequence the cell-free DNA methylome cost-effectively. Our machine-learning platform harnesses the cfDNA methylene data for sensitive and accurate Multi-Cancer Early Detection. | We are open-minded and happy to discuss. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Roshan Bhave | VeriSIM Life | roshan.bhave@verisimlife.com | San Francisco, CA | VeriSIM Life focuses on advancing drug development through hybrid AI/ML approaches. By integrating multi-omic tumor profiling, including key areas like genomics and proteomics, with cutting-edge machine learning algorithms, we aim to unravel tumor molecular landscapes. This approach enables us to predict drug responses, identify therapeutic targets, and optimize treatment strategies, driving more precise and personalized oncology therapies. | Teams that have experience in hardware / sensor based technology that can complement the intelligent software component that our team is specialized in developing | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Itamar Bitan | Dognosis | itamar@dognosis.tech | Bangalore, India | Dognosis is developing a $1 breath-based MCED screening test that will enhance follow-up diagnostics by identifying high-risk groups of asymptomatic patients. We combine nature's best olfactory sensor - the dog's nose - with a non-invasive brain-computer interface for dogs to create a digital signature of cancer scent | We're seeking partners who can complement our test with organ-specific follow-up diagnostics. Additionally, we're interested in collaborating with e-nose companies looking to expand their research and jointly develop a robust foundational olfaction model. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH |
| Katsuo Kurabayashi | New York University | kk5165@nyu.edu | New York City, NY | biosensors for ultrasensitive disease biomarker detection and liquid biopsy | low-abundant clinically proven cancer biomarkers | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Anastassia Kanavarioti | Yenos Analytical LLC | tessi.kanavarioti@gmail.com | El Dorado Hills, CA | We have developed a urine-based multi-cancer early detection test which is currently a laboratory-developed test. The science behind the test is based on the known microRNA dysregulation in cancers (blood samples) compared to healthy and proved by us to work in urine samples too. The detection is based on the MinION nanopore device commercialized by Oxford Nanopore Technologies and the probes are proprietary and manufactured by us. We wish to miniaturize this test for use at home. | The desired partner(s) may have software experience in single molecule ion conductance data acquisition and analysis, hardware experience in nanopore array design using proteinic or solid state nanopores of dimensions suitable for single strand nucleic acid translocation, or experience in developing a home-usable kit for total RNA isolation from urine. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Matheu Rouhier | Battelle | rouhier@battelle.org | Columbus, OH | World's largest not for profit research organization with best-in-class facilities and capabilities in organic chemistry, medical device development, data science, and health analytics. | Commercialization Partners, Clinical Data Specimen Gathering | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| David Trudil | New Horizons Diagnostics Corporation | Davidt@nhdetect.com | Baltimore, MD | GI CANCER biomarkers for cancer screening and therapeutic immunogen for treatment | cGMP pilot scale production and Clinical Trial support | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Dejan Nenov | Luventix Inc. | dejannenov@luventix.com | Henderson, NV | We are a small startup and have developed a urine-sample based platform that allows us to develop rule-out, screening and diagnostic tests for mulitple diseases. We process urine samples through Gas Chromatography and with the data train AI/ML models for individual diseases. The process of constructing and trainign a disease model is very efficient - it can take as few as 6 to 8 weeks and requries a relatively small number of samples - typically fewer than 300 hundred. | We would be interested in participating in any test development or clinical trial that collects uring samples from patients and would share with us 10mL+ of urine per patient. We would be happy to be part of a joint test development program, with a leading PI from the partner. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Daniel LaBarbera | CU Anschutz Center for Drug Discovery | daniel.labarbera@cuanschutz.edu | Aurora, CO | CU Anschutz focus areas include (1) access to care – through virtual health, a commitment to Medicaid and lower cost options, and continually expanding reach to rural and minority populations including Latinx and Tribal/Native American patients; (2) expanding and investing in behavioral health services for adults and children, including immigrant and refugee mental health services; and (3) innovation in diagnostics, treatment, and prevention. | We seek industry partnerships to develop advanced cancer detection kits, focusing on breath and urine analysis. This collaboration will encompass engineering, software development, and manufacturing to create cutting-edge diagnostic tools. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Rodrigo Mora | MediPro Direct | r.mora@mediprodirect.com | SALT LAKE CITY, UT | MediPro Direct is a phlebotomy and specimen collection network in all 50 states. We go to patients and collect samples then ship to your choice of lab. We can do device training, urine collection, blood draws, buccal swab testing, glucose testing, skin testing, ECGs, Vital Measurements, medical histories and cognitive testing. We are here to support your research. | There is no need for a hospital visit in some situations. We can get the blood biopsies, urine samples and send them to you. Reducing patient burden is essential. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH |
| Miguel Jimenez | Boston University | jmiguelj@bu.edu | Boston, MA | We develop microbial devices that integrate whole cells as the sensing elements inside electronic wireless devices. | We are looking for disease experts. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Diana Caldwell | Amplified Sciences | diana.caldwell@amplifiedsci.com | West Lafayette, IN | Amplified Sciences is a clinical stage life science in-vitro diagnostics startup company with an ultra-sensitive molecular-sensing platform technology with composition of matter IP exclusively licensed from Purdue University focused on accurately detecting debilitating diseases sooner. Their lead assay (PanCystProTM), a tool for risk stratification of pancreatic cancer demonstrates +95% NPV in ruling out potential malignancy in highrisk pancreatic cystic lesion patients. | Potential partners with a diagnostic kit format for breath or urine collection that integrates with our ultra-sensitive optical reporter platform that enables a new class of multi-omics diagnostic tests. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH |
| Jonathan Cohen | 20/20 GeneSystems, Inc. | jcohen@2020gene.com | Gaithersburg, MD | We offer the first multi-cancer early detection blood test using capillary specimens collected at home. | Marketing and distribution of our MCED. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Anu Mathew | Meso Scale Diagnostics, LLC. | amathew@mesoscale.com | ROCKVILLE, MD | Some of what MSD would bring to potential collaborations include: Experience in the production of highly sensitive, quantitative, and reproducible assays for biomarker measurements Highly developed protein and antibody production capabilities to support collaborative projects Experience in new technology development and assay automation Robust assay platform to benchmark other methodologies/technologies, and for standardization of biomarker measurements Cancer biomarker assay experience | Partners who could use MSD's capabilities in support of assay development | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Chandan Bhambhani | University of Michigan | bchandan@umich.edu | Ann Arbor, MI | The focus of our research is to develop biomarker assays for urine-based liquid biopsies. Our aim is to create non-invasive methodologies to aid early cancer detection, evaluate treatment effectiveness, and monitor post-treatment recurrences. Our recent publication highlights the characteristics of "trans-renal" cell-free tumor DNA, which transits from the blood stream into the urine and holds promise for urine-based detection of virtually any cancer type, including non-urologic cancers. | By leveraging single-stranded DNA sequencing and an innovative ddPCR assay, we have addressed some key challenges in the field of liquid biopsies. We have demonstrated the feasibility of developing a urine-based biomarker assay for a non-urologic cancer (HPV+ HNSCC). Our technical expertise is in biomarker discovery and early assay development, and we welcome collaborations to extend our findings to other cancer types for technological advancements, biomarker discovery, and clinical validation. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Brent Dixon | BioCytics | BDIXON@biocytics.com | Huntersville, NC | BioCytics, Inc's mission is to support early detection and provide treatment options for solid tumor patients. This is accomplished through its fully vertically integrated Human Applications Laboratory (HAL) GMP facility. HAL focuses on research, development and commercialization of assays, processes, and technologies for immunology applications. BioCytics is developing affordable individualized immune cellular therapies manufactured at the Point of Care (PoC). | Those who need 1) dedicated high complexity laboratory to refine or pilot their alpha or beta prototype; 2) biospecimens/genuine patient materials (IRB approved); 3) Leukapheresis immune cells, circulating tumor cells (CTCs), TDCCs and patient derived tumor organoids (PDTOs); 4) GMP optimization/scale up for manufacturing cell therapy IP and CDMO / CRO services IND drafting and submission to FDA for phase 1 clinical trials; 5) Phase 1 clinical trial site; 6) translational research and validation | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE, TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH |
| Fredrik Härenstam | Elypta | fredrik.harenstam@elypta.com | Stockholm, Sweden, MA | Elypta is a Swedish diagnostic company pioneering glycosaminoglycans (GAG) as a novel class of metabolic biomarkers to assess the risk and early development of multiple cancers while asymptomatic. Our goal is to commercialise affordable mass spectrometry (UPLC-MS/MS) IVD kits for small volumes of self-sampled urine supporting scalable distribution. GAGs appear to be powerful biomarkers for many cancer types (doi.org/10.1073/pnas.211532811) and complement clinical and genomic information. | Elypta is looking for further performance improvements from technological advancements and/or from combining additional biomarkers. We are open to team up with developers of other biomarkers and/or sensor technologies working with urine or breath samples. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Muneesh Tewari | University of Michigan | mtewari@med.umich.edu | Ann Arbor, MI | I am a Professor of Internal Medicine and Biomedical Engineering at the University of Michigan. I am also a medical oncologist and systems biologist. Our team has fundamental knowledge about trans-renal cell-free tumor DNA (ctDNA) in urine, which is an approach that can detect in principle cancer in any organ of the body, based on the transit of ctDNA from blood into urine. We have published on this, and also developed it for the urine-based detection of HPV-associated oropharyngeal cancer. | Our expertise is in discovering the right trans-renal ctDNA-based biomarkers for each different cancer type and developing assays (eg next gen sequencing-based, digital PCR, etc.). We would like to team up with partners who can collect samples broadly from patients and also develop products and implementation strategies. | |
| Oliver Nakano-Baker | University of Washington | onakanob+arpa-h.gov@gmail.com | Seattle, WA | - Biosensor development using peptide & ligand sensitizers for specific breath- and fluid-born analyte detection - Peptide and ligand design for targeted VOC and biomacromolecule binding - Specific VOC biomarker in breath matrix detection at <1 part-per-billion concentrations - Specific macromolecule detection in solution to <1 nanomolar concentrations - Binder multiplexing for efficient multi-indication sensor design - Additive electronics processing for low-cost sensor manufacturing (<$1/chip) | We would like to design and scale an affordable multiplex transistor package for single-shot detection of multiple breath and/or urine biomarkers from a single sample to screen the full compliment of tumor indications targeted by POSEIDON. We would compliment a team comprised of biomarker selection and validation, mechanical platform, clinical study, and regulatory expertise. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH, TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Ping Yeh | Vocxi Health | ping.yeh@vocxihealth.com | Arden Hills, MN | Vocxi Health has developed a sensor array platform that leverages novel chemistry and machine learning that digitizes breath (VOCs) to determine the presence of disease at all stages. We are a Boston Scientific and University of Minnesota clinical-stage spinout that is now focused in characterizing breathprint patterns for various cancers and their subtypes. This is a platform that can extend beyond our cancer focus. We have completed feasibility studies in chemical and biological threats. | We are looking for partners who have leading expertise in the following areas: Disease/Oncology experts with patient access, Advanced Signal Processing, Advanced instrumentation (e.g. time-of-flight mass spectroscopy), AI/Data Analytics, Cell culturing capability, EHR Integration, System Administration, Telemedicine, Omics analysis. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH |
| Dejan Nenov | Luventix Inc. | dejannenov@luventix.com | Henderson, NV | At Luventix, we have developed a platform that uses GC processing (wet lab) and then AI/ML analysis (dry lab) to diagnose mulitple diseases from a single urine sample. The platform allows rapid, mechanistic development of disease models from a few hundred positive samples and a control group. | We would be thrilled to be the junior partner to any orgnaization that will engage in this progrm, if the partner is willing to collect urine sampes, as part fo their research and/or clinicalr studies/trials, which we can use to build models for the cancers that the partner is focused on. Another partnership path is with medical device manufacturers (hardware), which we can help develop a point of care and/or at hoem device to perfrom Luventix tests from urine samples. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Floyd Taub | aiGENE, Inc. | FloydTaub@a-i-GENE.com | Aurora, CO | Devices to quickly, without degration, inexpensively, in any setting including at home, collect, purify, ship at ambient temperature, and separately analyze cfDNA from 100s of mls to a full days urine output. | Teams using various methods to analyze cfDNA, that want to expand to at home or WW use. We are especially looking to team with both drugs and diagnostic companies in trials who may want frequent, even daily, sampling. As we collect up to 100x more cfDNA than other methods detection of rare sequences is facilitated. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Gabe Meister | Battelle | meisterg@battelle.org | Columbus, OH | Battelle is the largest independent non-profit R&D organization in the US. We work in the markets of health, environment, and national security. In the market of health, we have multidisciplinary teams that develop disruptive technologies that enable the development and commercialization of effective diagnostic, therapeutic, and prophylactic products. Please connect for additional details. | Expertise in at home diagnostic deployment. Breadth of clinical specimens to validate target ID. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH |
| Sean McIntosh | Foothold Labs Inc. | sean@footholdlabs.com | Olathe, KS | Electrochemical biosensors paired with machine learning software using immobilized bioreagents such as antibodies, aptamers, or peptides as the biorecognition element to produce label free quantitative results in complex matrices such as urine or saliva. | Software development, pre-clinical trial testing, & manufacturing | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - BREATH |
| Dmitri Kapitonov | Unimer Technology | Dmitri.Kapitonov@hsc.utah.edu | Salt Lake City, UT | 1) Recombinant protein production in mutant microorganism. 2) Massively parallel development of antibody mimetics with pre-determined specificity. | Large scale bioreactor GMP capacity | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Angela Webb | Immertec | Angela.webb@immertec.com | Washington, DC | Immertec's research focuses on developing and deploying innovative solutions that enhance medical training and education, particularly by improving the deployment and training related to advanced medical diagnostics. | Immertec would be looking for a partner with expertise in biotechnology, diagnostics, or healthcare services that is leading the development of multi-cancer early detection tests for the project. Immertec would serve as a partner, providing specialized training and educational support, particularly focused on preparing healthcare professionals and patients to effectively use and interpret at-home diagnostic tests, ensuring successful adoption and proper usage. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Mehdi Hatamian | 2Pi-Sigma Corp. | mehdi@2pisigma.com | Newport Beach, CA | 2Pi-Sigma Corp. is developing low cost ($50/test) rapid at home cancer screening tests for early detection of majority of cancers as a fully integrated device using a few microliters of blood. 2Pi-Sigma Corp. has developed a new generation of LFA technology and a microfluidics platform enabling the development of its rapid test (NovoScreenTM). 2Pi-Sigma owns a portfolio of 58 patents on its technologies and assays and is total control of manufacturing and purifying its proprietary antibody. | Open for discussions | . |
| Aras Eftekhari | Velsera | aras.eftekhari@gmail.com | Fairfax, VA | Velsera empowers researchers, scientists & clinicians to drive precision R&D, expand access to omics, and more effectively leverage analytics at the point of care. We unify technology- enabled solutions and scientific expertise to enable a continuous flow of knowledge across the global healthcare ecosystem. This interweaves diverse biomedical communities, allowing them to build upon each other's successes and accelerate medical breakthroughs that positively impact human health. | We are looking for partners that can benefit from our platforms and expertise. From our Fedramp Moderate Multiomics platform Seven Bridges, our Clinical Genomics Workspace that offers clinical reporting and diagnostic solutions, and/or our FastFinder lab workflow automation and quality control. | |
| Sonia Grego | Coprata | sonia@coprata.com | Durham, NC | Coprata is an early stage technology company with the mission to improve health through data from smart toilets. Coprata has developed a hardware solution to address the barrier to specimen collection of stool by creating the first of its kind sampling toilet solution that collects specimen automatically post-flush, with complete absences of physical, visual, smell interactions. The Sampling Toilet is easy to install in the home, easy to operate for long-term passive specimen collection forall. | We are seeking partners with assay and sensors solution that benefit from accessing excreta specimen automatically, hands-free and with routine use of the toilet. Our hardware toilet solution provides unprecedented access to stool as well as the ability for passive urine collection. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Ashish Chaudhary | Detect-ION | Ashish.Chaudhary@detect-ion.com | Tampa, FL | Detect-ION develops next-gen CBRNE sensors in a dedicated state-of-the-art 4000 sqft laboratory located in Tampa, FL. We thrive in solving hard detection problems that require a multidisciplinary effort at the intersection of organic chemistry, biochemistry, gas chromatography, mass spectrometry, vacuum technology, data analytics, low power electronics, system engineering and AI/ML algorithm to innovate the most pioneering sensors for health diagnostics, public safety and national security. | Detect-ION is developing portable, high-performance volatile organic compounds (VOCs) sensors for both Breath and Urine-based media and is looking for oncology clinical partners to evaluate the feasibility and efficacy of VOC-based analyses as an early multi-cancer in-home diagnostic. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Hongzhang He | Captis Diagnostics | simonhe@captisdx.com | Pittsburgh, PA | Captis Diagnostics is developing liquid biopsy technology based on extracellular vesicles to create minimally invasive diagnostic tools and assays for cancer. These innovative diagnostic assays will provide medical doctors with actionable insights for treating cancer, ultimately leading to improved patient outcomes. | synthetic biology, molecular sensor | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Karen Kimbro | Verizon | karen.kimbro@verizon.com | ashburn, VA | Verizon supports the connectivity and integration of home clinical trials to integration platforms and transport to destination in a secure timely persistent manner. We are currently supporting home based clinical trials at the VA. The communications aspect is often overlooked at it is not a core clinical capability, yet it is fundamental to the overall solultion. We also augment communcation gaps in rural areas with our low earth orbit satellite capability. | We are looking for teaming partners who are providingthe clinical solutions and in particular the integration solution in TA2 such that we can enable safe secure persistent communications. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Vrad Levering | Triple Ring Technologies | vlevering@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products across medtech, life sciences, and sustainability. Our interdisciplinary team, including many PhDs, excels in advancing technologies up the TRL scale and collaborating with academic researchers. We have a strong track record of engaging with ARPA-H, both as subcontractors and primary awardees. We offer services from basic tech development to prototype design and manufacturing. Fully ISO 13485 certified. | We partner with innovators to solve tough problems, launch breakthrough products, and create new businesses. From concept to FDA submission and commercialization, we handle technology development and redesign, as well as complex system integration. We welcome teaming partners with medical or specific domain expertise, and encourage bold ideas beyond current limits. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| John Powderly MD | Carolina BioOncology Institute, PLLC & BioCytics Inc | jpowderly@carolinabiooncology.org | Huntersville, NC, USA, NC | Metastatic Solid tumor cancer immunotherapy options on early phase clinical trials, and cell therapies R&D | CBOI Phase 1 cancer clinic and BioCytics Human Applications Lab have a biospecimen research trial which has been accruing since 2007, and used for cross-validation of cancer patient samples with healthy volunteer to determine clinical utility of diagnostic tests for cancer detection and molecular profiling. We are particularly interested in urine based tests of extra-cellular vesicles for broad cancer mutant MUC1 positivity and other molecular markers on EVs shed into the urine, and/or blood. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Ben Krasnow | Verily | bkrasnow@verily.com | South San Francisco, CA | Verily has studied endogenous and exogenous breath and urine biomarkers for the detection of several diseases since 2020. We have concentrated on exogenous urine biomarkers for early cancer detection, and have preliminary results showing promise with a novel fluorescent probe compound. | We are looking for help with the design of novel chemical compounds that can enhance the system's efficiency. We are also looking to partner with other cancer researchers who have experience with small molecule transport and tracking inside a tumor. We would also be interested in collaboration with teams working on an at-home test kit. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Arash Takshi | University of South Florida | atakshi@usf.edu | Tampa, FL | Our team at USF is working on an electronic nose technology for cancer screening applications | We would like to team up with partners who can helps us for sample collections and analysis and finally FDA approval of the system that we are developing. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| Sameer Sonkusale | Tufts University | sameer@ece.tufts.edu | Medford, MA | Tufts University | Development of synbio receptors | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |
| Mohammed Eslami | Netrias, LLC | meslami@netrias.com | Annapolis, MD | We focus on the harmonization, integration, and analysis of disease agnostic datasets to identify biomarkers that can be combined indicative of disease state. We build light-weight ensemble models that can be deployed to the device. We also have expertise on optimizing software to run on the device to enable sensing, processing, and decision making. | We are looking for partners with experience in sensor development and oncology. | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - BREATH |
| Nicholas Kotov | University of Michigan | kotov@umich.edu | Ann Arbor, MI | Rapid separation of exosomes and other extracellular vesicles without ultracentrifugation. Label-free biosensing of exosomes and rapid detection of mutated proteins in them using nanoparticles. | Access to cancer patients. Clinical samples. | TA1: Sensor and synthetic reporter development for Multi-Cancer Early Detection (MCED) - URINE |
| ehsan sheybani | USF | sheybani@usf.edu | Tampa, FL | We are experimenting with hybrid modular sensors with urine, breath, and blood to detect cancer using advanced AI/ML algorithms | hybrid modular sensors | TA2: A cancer screening kit for Multi-Cancer Early Detection (MCED) - URINE |